Foundation Fighting Blindness Fund Sells $2.76M of Opus Genetics Stock
IRD has more than doubled off its 52-week low of $1.7.
Summary
Director-affiliated Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics for $2.76 million, retaining 3.24 million shares.
Key Events · Ownership and Investor Activity · IRD
-
Director-Affiliated Fund Sells 556,000 Shares
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares at a weighted average price of $4.9568 for total proceeds of $2,755,980.80 on September 30, 2026.
-
Post-Sale Holdings of 3.24M Shares
The fund retains 3,236,171 shares after the sale, representing a 14.7% reduction in its position.
-
Largest Insider Sale in 90 Days
This $2.76M sale exceeds the combined $140,866 in open-market insider sales over the prior 90 days, marking a significant shift in insider distribution activity.
-
Sale Follows Positive Clinical Data
The sale comes three weeks after positive Phase 1/2 data for OPGx-BEST1 was reported on September 9, 2026, suggesting profit-taking or portfolio rebalancing by the fund.
Analysis · IRD · Life Sciences
A director-affiliated entity, the Foundation Fighting Blindness Retinal Degeneration Fund, sold 556,000 shares for approximately $2.76 million at a weighted average price of $4.96 on September 30, 2026. The sale represents a meaningful reduction in the fund's position, though it retains 3.24 million shares. This is the largest insider sale in the last 90 days and comes after a period of positive clinical data for OPGx-BEST1, suggesting the fund is taking profits or rebalancing its portfolio.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1528 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRD was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $381M. The 52-week trading range was $1.70 to $7.07. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.